Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis

Authors: Myrthe P. P. van Herk‐Sukel, Lonneke V. van de Poll‐Franse, Adri C. Voogd, Grard A. P. Nieuwenhuijzen, J.W.W. Coebergh, Ron M. C. Herings - Breast Cancer Research and Treatment 2010 cited by 140